Intellia Therapeutics Inc
NTLA12.230USD
+0.740+6.44%
交易中 （美东）报价延迟15分钟
1.27B总市值
亏损市盈率 TTM
关于 Intellia Therapeutics Inc 公司
Intellia Therapeutics, Inc. 是一家临床阶段的基因组编辑公司，专注于使用成簇、规律间隔的短回文重复序列/CRISPR 相关 9 (CRISPR/Cas9) 技术开发治愈性疗法。CRISPR/Cas9 是一种基因组编辑技术，即改变基因组脱氧核糖核酸的选定序列的过程。该公司专注于利用其模块化平台推进体内和体外治疗高度未满足需求的疾病。其领先的体内候选药物 NTLA-2001 用于治疗转甲状腺素蛋白 (ATTR) 淀粉样变性，而 NTLA-2002 用于治疗遗传性血管性水肿 (HAE)，是首批通过静脉 (IV) 输注全身给药的基于 CRISPR/Cas9 的治疗候选药物，用于精确编辑人类靶组织中的基因。该公司还在开发体外应用以治疗免疫肿瘤学和自身免疫性疾病。
公司简介
公司代码NTLA
公司名称Intellia Therapeutics Inc
上市日期May 06, 2016
CEODr. John M. Leonard, M.D.
员工数量403
证券类型Ordinary Share
年结日May 06
公司地址40 Erie St Ste 130
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02139-4254
电话18572856200
网址https://www.intelliatx.com/
公司代码NTLA
上市日期May 06, 2016
CEODr. John M. Leonard, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
19.97K
+66.85%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
18.80K
+74.05%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
16.62K
-8.51%
Mr. Michael P. Dube
Mr. Michael P. Dube
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
4.52K
-35.64%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
收入明细
FY2025Q1
FY2024
FY2023
FY2022
暂无数据
地区USD
名称
营收
占比
United States
16.63M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月18日 周五
更新时间: 7月18日 周五
持股股东
股东类型
持股股东
持股股东
占比
ARK Investment Management LLC
12.57%
The Vanguard Group, Inc.
10.36%
BlackRock Institutional Trust Company, N.A.
8.12%
State Street Global Advisors (US)
4.35%
Two Sigma Investments, LP
3.84%
Other
60.76%
持股股东
持股股东
占比
ARK Investment Management LLC
12.57%
The Vanguard Group, Inc.
10.36%
BlackRock Institutional Trust Company, N.A.
8.12%
State Street Global Advisors (US)
4.35%
Two Sigma Investments, LP
3.84%
Other
60.76%
股东类型
持股股东
占比
Investment Advisor
50.59%
Investment Advisor/Hedge Fund
20.47%
Hedge Fund
14.23%
Research Firm
6.53%
Corporation
3.57%
Individual Investor
1.49%
Bank and Trust
0.78%
Pension Fund
0.32%
Private Equity
0.22%
Other
1.79%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
699
101.80M
98.27%
-16.60M
2025Q1
734
106.27M
102.60%
-9.72M
2024Q4
721
99.85M
96.57%
-1.86M
2024Q3
722
94.22M
92.84%
-2.81M
2024Q2
726
90.26M
93.51%
-7.71M
2024Q1
739
91.00M
94.49%
-893.96K
2023Q4
792
85.05M
91.49%
-3.09M
2023Q3
802
83.74M
94.78%
-6.96M
2023Q2
821
81.86M
93.61%
-7.70M
2023Q1
811
82.36M
94.28%
-4.97M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
ARK Investment Management LLC
13.01M
12.56%
+474.63K
+3.79%
Mar 31, 2025
The Vanguard Group, Inc.
10.73M
10.36%
+561.98K
+5.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
8.12%
-411.95K
-4.67%
Mar 31, 2025
State Street Global Advisors (US)
4.51M
4.35%
-695.44K
-13.36%
Mar 31, 2025
Two Sigma Investments, LP
3.98M
3.84%
+120.05K
+3.11%
Mar 31, 2025
Capital International Investors
3.78M
3.65%
+3.78M
--
Mar 31, 2025
Regeneron Pharmaceuticals Inc
3.70M
3.57%
--
--
Mar 31, 2025
Citadel Advisors LLC
2.76M
2.66%
+263.50K
+10.56%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
2.83M
2.73%
-167.30K
-5.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.48M
2.39%
+90.93K
+3.81%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ARK Genomic Revolution ETF
2.65%
WisdomTree BioRevolution Fund
2.48%
ARK Innovation ETF
1.25%
Global X Genomics & Biotechnology ETF
1.17%
Virtus LifeSci Biotech Clinical Trials ETF
1.01%
Tema Neuroscience and Mental Health ETF
0.54%
SPDR S&P Biotech ETF
0.31%
Tema Heart & Health ETF
0.23%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Avantis US Small Cap Equity ETF
0.12%
查看更多
ARK Genomic Revolution ETF
占比2.65%
WisdomTree BioRevolution Fund
占比2.48%
ARK Innovation ETF
占比1.25%
Global X Genomics & Biotechnology ETF
占比1.17%
Virtus LifeSci Biotech Clinical Trials ETF
占比1.01%
Tema Neuroscience and Mental Health ETF
占比0.54%
SPDR S&P Biotech ETF
占比0.31%
Tema Heart & Health ETF
占比0.23%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.17%
Avantis US Small Cap Equity ETF
占比0.12%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
